Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

In patients who had undergone stem-cell transplantation, lenalidomide maintenance therapy improved progression-free and overall survival, though at the expense of some increased hematologic toxicity and second malignant tumors. A goal of therapy for multiple myeloma, to induce complete remission and...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:The New England journal of medicine Ročník 366; číslo 19; s. 1770 - 1781
Hlavní autoři: McCarthy, Philip L, Owzar, Kouros, Hofmeister, Craig C, Hurd, David D, Hassoun, Hani, Richardson, Paul G, Giralt, Sergio, Stadtmauer, Edward A, Weisdorf, Daniel J, Vij, Ravi, Moreb, Jan S, Callander, Natalie Scott, Van Besien, Koen, Gentile, Teresa, Isola, Luis, Maziarz, Richard T, Gabriel, Don A, Bashey, Asad, Landau, Heather, Martin, Thomas, Qazilbash, Muzaffar H, Levitan, Denise, McClune, Brian, Schlossman, Robert, Hars, Vera, Postiglione, John, Jiang, Chen, Bennett, Elizabeth, Barry, Susan, Bressler, Linda, Kelly, Michael, Seiler, Michele, Rosenbaum, Cara, Hari, Parameswaran, Pasquini, Marcelo C, Horowitz, Mary M, Shea, Thomas C, Devine, Steven M, Anderson, Kenneth C, Linker, Charles
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Massachusetts Medical Society 10.05.2012
Témata:
Adult
Aged
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Autografts
Cancer
Cancer therapies
Clinical trials
Disease-Free Survival
Double-Blind Method
Female
Follow-Up Studies
Humans
Immunotherapy
Lenalidomide
Maintenance Chemotherapy
Male
Middle Aged
Multiple myeloma
Multiple Myeloma - drug therapy
Multiple Myeloma - mortality
Multiple Myeloma - therapy
Neoplasms, Second Primary - epidemiology
Stem Cell Transplantation
Targeted cancer therapy
Thalidomide - adverse effects
Thalidomide - analogs & derivatives
Thalidomide - therapeutic use
Toxicity
Transplants & implants
ISSN:0028-4793, 1533-4406, 1533-4406
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:In patients who had undergone stem-cell transplantation, lenalidomide maintenance therapy improved progression-free and overall survival, though at the expense of some increased hematologic toxicity and second malignant tumors. A goal of therapy for multiple myeloma, to induce complete remission and prolong survival, is usually accomplished with combination therapy. 1 , 2 Autologous hematopoietic stem-cell transplantation is often used after induction chemotherapy to improve the response or to consolidate complete remission. 1 , 2 However, since most patients with multiple myeloma have disease recurrence or progression after transplantation, maintenance therapies have been used to prolong complete remission and prevent relapse or progressive disease. Low-dose melphalan, interferon alfa, and glucocorticoids have been used for maintenance after primary therapy, but their long-term use is limited by toxicity and modest efficacy. 3 – 6 Five studies involving patients who . . .
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa1114083